Compare AbCellera Biologics Inc (ABCL) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs D Wave Quantum Inc — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while D Wave Quantum Inc trades at $20.62 (market cap $7.80B). The key difference: D Wave Quantum Inc is far larger — about 3.3× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | QBTS | |
|---|---|---|
Market Cap | $2.35B | $7.80B |
Sector | Health | Technology |
52-Week High | $8.12 | $44.78 |
52-Week Low | $2.78 | $12.98 |
Enterprise Value | $1.99B | $7.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
D-Wave Quantum (QBTS) trades at $22.56, up 0.11% on the day, amid a bearish technical signal from moving averages. The company reported a net loss of $355.06 million on $24.59 million revenue in 2025, with a negative net income margin of -2,957.23%. Recent positive developments include being named a Leader in the IDC MarketScape quantum computing assessment and securing a $1.5 million NSF grant.
Despite unanimous analyst buy ratings and a $39.86 consensus price target, significant risks include extreme cash burn, negative profitability, and the speculative nature of quantum computing commercialization. The stock's high P/S ratio of 619.05 reflects growth expectations but underscores valuation sensitivity to execution milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
